Stock INAB IN8BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News IN8bio, Inc.

Equities

INAB

US45674E1091

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-06 pm EDT 		5-day change 1st Jan Change
0.9981 USD -0.19% Intraday chart for IN8bio, Inc. +0.81% -27.67%
Apr. 30 In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma CI
Apr. 10 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
AQ
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma
CI
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting
AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
AQ
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
AQ
Top Premarket Gainers
MT
North American Morning Briefing: Traders Await the CPI Report
DJ
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
AQ
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
CI
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target
MT
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
AQ
JonesTrading Starts IN8bio With Buy Rating, $5 Price Target
MT
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
AQ
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
CI
IN8bio to Present at Upcoming Investor Conferences
BU
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
AQ
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
CI
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
AQ
IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INAB Stock
  4. News IN8bio, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW